Presentation TCT 2025 TCT 1246: Intracoronary imaging plaque vulnerability characteristics predictors of MACE: an updated meta-analysis of adjusted observational studies Presenter: Riccardo Improta October 26, 2025
Presentation TCT 2025 TCT 689: Beyond Stent Optimisation: Impact of Pre-PCI Planning on Edge Dissection and MACE Presenter: Nitin Chandra Mohan October 26, 2025
News Daily News Semaglutide’s CV Effects Only Partially Tied to Weight Loss: SELECT Analysis Yael L. Maxwell October 24, 2025
News Daily News Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients Caitlin E. Cox October 22, 2025
News Opinion Editor's Corner TCT 2025 What’s Going to Be Hot at TCT 2025 Michael O'Riordan October 09, 2025
News Daily News Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s Michael O'Riordan September 18, 2025
News Daily News AI Tool Supports Mammograms as Method to Screen Women for CV Risk Caitlin E. Cox September 18, 2025
News Conference News ESC 2025 DAPT’s Role After CABG Questioned: TACSI and TOP-CABG Caitlin E. Cox September 05, 2025
News Conference News ESC 2025 NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure Michael O'Riordan September 04, 2025
News Conference News ESC 2025 No Benefit to Routine CT Angiography After Left Main PCI: PULSE Michael O'Riordan August 31, 2025
News Conference News ESC 2025 Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF Michael O'Riordan August 30, 2025
News Daily News Evolocumab Gains Expanded Indication for Primary Prevention Michael O'Riordan August 26, 2025
News Daily News DAPT De-escalation Success Varies by Sex: Meta-analysis Yael L. Maxwell August 21, 2025
News Daily News With MISSION Act, Veterans Get More Convenient but Potentially Worse CV Care Yael L. Maxwell August 08, 2025
News Daily News Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol Michael O'Riordan August 06, 2025
News Daily News Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks Michael O'Riordan August 01, 2025
News Daily News Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT Michael O'Riordan July 31, 2025